Exploring the efficacy of tryptone-stabilized silver nanoparticles against respiratory tract infection-causing bacteria: a study on planktonic and biofilm forms.

Respiratory tract infections are a common cause of mortality and morbidity in the human population. The overuse of antibiotics to overcome such infections has led to antibiotic resistance. The emergence of Multidrug resistant (MDR) bacteria is necessitating the development of novel therapeutic techniques in order to avoid a major global clinical threat. Our study aims to investigate the potential of Tryptone stabilised silver nanoparticles (Ts-AgNPs) on planktonic and biofilms produced by Klebsiella pneumoniae and Pseudomonas aeruginosa. The MIC50 of Ts-AgNPs was found to be as low as 1.7 μg/mL and 2.7 μg/mL for K. pneumoniae and P.aeruginosa respectively. Ts-AgNPs ability to alter redox environment by producing intracellular ROS, time-kill curves showing substantial decrease in the bacterial growth and significantly reduced colony forming units further validate its antimicrobial effect. The biofilm inhibition and eradication ability of Ts-AgNPs was found to be as high as 93% and 97% in both the tested organisms. A significant decrease in the eDNA and EPS quantity in Ts-AgNPs treated cells proved its ability to successfully distort the matrix and matured biofilms. Interestingly Ts-AgNPs also attenuated QS-induced virulence factors production,. This study paves way to develop Ts-AgNPs as novel antibiotics against respiratory tract infections causing bacterial biofilms.&#xD.